Evidence map›Paper›PMID 26537685›Full record

ArticleJournal of virology2016

Structural Insights into HIV-1 Vif-APOBEC3F Interaction.

Masaaki Nakashima, Hirotaka Ode, Takashi Kawamura, Shingo Kitamura, Yuriko Naganawa, Hiroaki Awazu, Shinya Tsuzuki, Kazuhiro Matsuoka, Michiko Nemoto, Atsuko Hachiya and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. HIV Genome-Wide Protein Associations: a Review of 30 Years of Research.Microbiology and molecular biology reviews : MMBR · 2016
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Characterization of an A3G-VifMolecular & cellular proteomics : MCP · 2021
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Structural perspectives on HIV-1 Vif and APOBEC3 restriction factor interactions.Protein science : a publication of the Protein Society · 2020
    Review
  16. Article
  17. Structural basis of antagonism of human APOBEC3F by HIV-1 Vif.Nature structural & molecular biology · 2019
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Masaaki NakashimaClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan Department of Biotechnology, Nagoya University Graduate School of Engineering, Nagoya, Aichi, Japan.
Hirotaka OdeClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan.
Takashi KawamuraSynchrotron Radiation Research Center, Nagoya University, Nagoya, Aichi, Japan.
Shingo KitamuraClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan Department of Biotechnology, Nagoya University Graduate School of Engineering, Nagoya, Aichi, Japan.
Yuriko NaganawaClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan.
Hiroaki AwazuClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan Department of Biotechnology, Nagoya University Graduate School of Engineering, Nagoya, Aichi, Japan.
Shinya TsuzukiClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan Department of Biotechnology, Nagoya University Graduate School of Engineering, Nagoya, Aichi, Japan.
Kazuhiro MatsuokaClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan.
Michiko NemotoClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan.
Atsuko HachiyaClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan.
Wataru SugiuraClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan Division of Basic Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Yoshiyuki YokomakuClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan.
Nobuhisa WatanabeDepartment of Biotechnology, Nagoya University Graduate School of Engineering, Nagoya, Aichi, Japan Synchrotron Radiation Research Center, Nagoya University, Nagoya, Aichi, Japan.
Yasumasa IwataniClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan Division of Basic Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan iwataniy@nnh.hosp.go.jp.
Nagoya Medical Center · JPNagoya University · JPNational Hospital Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledThe HIV-1 Vif protein inactivates the cellular antiviral cytidine deaminase APOBEC3F (A3F) in virus-infected cells by specifically targeting it for proteasomal degradation. Several studies identified Vif sequence motifs involved in A3F interaction, whereas a Vif-binding A3F interface was proposed based on our analysis of highly similar APOBEC3C (A3C). However, the structural mechanism of specific Vif-A3F recognition is still poorly understood. Here we report structural features of interaction interfaces for both HIV-1 Vif and A3F molecules. Alanine-scanning analysis of Vif revealed that six residues located within the conserved Vif F1-, F2-, and F3-box motifs are essential for both A3C and A3F degradation, and an additional four residues are uniquely required for A3F degradation. Modeling of the Vif structure on an HIV-1 Vif crystal structure revealed that three discontinuous flexible loops of Vif F1-, F2-, and F3-box motifs sterically cluster to form a flexible A3F interaction interface, which represents hydrophobic and positively charged surfaces. We found that the basic Vif interface patch (R17, E171, and R173) involved in the interactions with A3C and A3F differs. Furthermore, our crystal structure determination and extensive mutational analysis of the A3F C-terminal domain demonstrated that the A3F interface includes a unique acidic stretch (L291, A292, R293, and E324) crucial for Vif interaction, suggesting additional electrostatic complementarity to the Vif interface compared with the A3C interface. Taken together, these findings provide structural insights into the A3F-Vif interaction mechanism, which will provide an important basis for development of novel anti-HIV-1 drugs using cellular cytidine deaminases. IMPORTANCE: HIV-1 Vif targets cellular antiviral APOBEC3F (A3F) enzyme for degradation. However, the details on the structural mechanism for specific A3F recognition remain unclear. This study reports structural features of interaction interfaces for both HIV-1 Vif and A3F molecules. Three discontinuous sequence motifs of Vif, F1, F2, and F3 boxes, assemble to form an A3F interaction interface. In addition, we determined a crystal structure of the wild-type A3F C-terminal domain responsible for the Vif interaction. These results demonstrated that both electrostatic and hydrophobic interactions are the key force driving Vif-A3F binding and that the Vif-A3F interfaces are larger than the Vif-A3C interfaces. These findings will allow us to determine the configurations of the Vif-A3F complex and to construct a structural model of the complex, which will provide an important basis for inhibitor development.

Indexed as

Crystallography, X-RayCytidine DeaminaseCytosine DeaminaseDNA Mutational AnalysisModels, MolecularMutagenesis, Site-DirectedProtein ConformationProtein Interaction MappingProteolysisvif Gene Products, Human Immunodeficiency VirusAPOBEC3C protein, humanAPOBEC3F protein, humanCytidine DeaminaseCytosine Deaminasevif Gene Products, Human Immunodeficiency Virusvif protein, Human immunodeficiency virus 1

Identifiers

PMID26537685
PMCPMC4702671
OpenAlexW2166630478

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.